BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 14968476)

  • 1. [New molecular features of cholestatic diseases of the liver].
    Méndez-Sánchez N; Chavez-Tapia NC; Uribe M
    Rev Invest Clin; 2003; 55(5):546-56. PubMed ID: 14968476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New molecular aspects of cholestatic liver diseases].
    Trauner M; Fickert P; Stauber RE
    Z Gastroenterol; 1999 Jul; 37(7):639-47. PubMed ID: 10458013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocellular bile salt transport: lessons from cholestasis.
    Trauner M; Fickert P; Stauber RE
    Can J Gastroenterol; 2000 Nov; 14 Suppl D():99D-104D. PubMed ID: 11110621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The expression levels of plasma membrane transporters in the cholestatic liver of patients undergoing biliary drainage and their association with the impairment of biliary secretory function.
    Shoda J; Kano M; Oda K; Kamiya J; Nimura Y; Suzuki H; Sugiyama Y; Miyazaki H; Todoroki T; Stengelin S; Kramer W; Matsuzaki Y; Tanaka N
    Am J Gastroenterol; 2001 Dec; 96(12):3368-78. PubMed ID: 11774951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular alterations of canalicular transport systems in experimental models of cholestasis: possible functional correlations.
    Trauner M
    Yale J Biol Med; 1997; 70(4):365-78. PubMed ID: 9626757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pathophysiology of cholestasis with special reference to primary biliary cirrhosis.
    Jansen PL
    Baillieres Best Pract Res Clin Gastroenterol; 2000 Aug; 14(4):571-83. PubMed ID: 10976015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis.
    Trauner M; Wagner M; Fickert P; Zollner G
    J Clin Gastroenterol; 2005 Apr; 39(4 Suppl 2):S111-24. PubMed ID: 15758646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholestatic liver diseases: slow progress in understanding and treating slowly progressive disorders.
    Vleggaar FP; Van Ooteghem NA; Van Buuren HR; Van Berge Henegouwen GP
    Scand J Gastroenterol Suppl; 2000; (232):86-92. PubMed ID: 11232499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic variations of bile salt transporters as predisposing factors for drug-induced cholestasis, intrahepatic cholestasis of pregnancy and therapeutic response of viral hepatitis.
    Stieger B; Geier A
    Expert Opin Drug Metab Toxicol; 2011 Apr; 7(4):411-25. PubMed ID: 21320040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics of hepatocellular transporters.
    Pauli-Magnus C; Meier PJ
    Pharmacogenetics; 2003 Apr; 13(4):189-98. PubMed ID: 12668915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanisms of cholestasis.
    Zollner G; Trauner M
    Wien Med Wochenschr; 2006 Jul; 156(13-14):380-5. PubMed ID: 16937039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Intrahepatic cholestasis].
    Adachi Y; Kamisako T
    Nihon Rinsho; 1996 Mar; 54(3):788-93. PubMed ID: 8904238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A nontumorigenic variant of FGF19 treats cholestatic liver diseases.
    Luo J; Ko B; Elliott M; Zhou M; Lindhout DA; Phung V; To C; Learned RM; Tian H; DePaoli AM; Ling L
    Sci Transl Med; 2014 Jul; 6(247):247ra100. PubMed ID: 25080475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of farnesoid X receptor in cholestasis.
    Yuan ZQ; Li KW
    J Dig Dis; 2016 Aug; 17(8):501-509. PubMed ID: 27383832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptional regulation of hepatobiliary transport systems in health and disease: implications for a rationale approach to the treatment of intrahepatic cholestasis.
    Wagner M; Trauner M
    Ann Hepatol; 2005; 4(2):77-99. PubMed ID: 16010241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocellular transporters and cholestasis.
    Pauli-Magnus C; Meier PJ
    J Clin Gastroenterol; 2005 Apr; 39(4 Suppl 2):S103-10. PubMed ID: 15758645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatobiliary transporters and drug-induced cholestasis.
    Pauli-Magnus C; Meier PJ
    Hepatology; 2006 Oct; 44(4):778-87. PubMed ID: 17006912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The descending pathophysiology model of cholestatic liver disease].
    Cai XB; Lu LG
    Zhonghua Gan Zang Bing Za Zhi; 2019 May; 27(5):321-324. PubMed ID: 31177654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bile acid metabolism and FXR-mediated effects in human cholestatic liver disorders.
    Molinaro A; Marschall HU
    Biochem Soc Trans; 2022 Feb; 50(1):361-373. PubMed ID: 35191955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular mechanisms of bile formation and cholestatic diseases].
    Poupon R
    Bull Acad Natl Med; 2003; 187(7):1261-74; discussion 1274-6. PubMed ID: 15146603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.